egfr mutation testing guidelines
egfr testing lung cancerlung cancer molecular testing algorithm
lung cancer molecular testing guidelines 2017
lung cancer molecular testing guidelines 2018
asco guidelines molecular testing lung cancer

Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we6.1: Recommendation: Laboratories may use any validated EGFR testing method with sufficient performance characteristics. 6.2: Expert consensus opinion: Laboratories should use EGFR test methods that are able to detect mutations in specimens with at least 20 % cancer cell content. update and revise the 2013 evidence-based "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. 5 Feb 2018 The molecular testing guideline was reviewed for developmental rigor by immunohistochemistry for selection of patients for EGFR-targeted 22 Jan 2018 Strong Recommendation: Laboratories should not use total EGFR expression by IHC testing to select patients for EGFR-targeted tyrosine kinase inhibitor therapy. Strong Recommendation: ROS1 testing must be performed on all lung adenocarcinoma patients, irrespective of clinical characteristics. Objective. To establish evidence-based recommendations for the molecular analysis of lung cancers that are that are required to guide EGFR- and ALK-directed 22 Jan 2018 Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients against the use of immunohistochemistry for EGFR testing. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients Inhibitors,” which establishes standards for EGFR and ALK testing, helping to The 2017 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for . Testing for EGFR, ALK, and ROS1 are category 1 recommendations. PD-L1 22 Jan 2018 use of 5% sensitivity assays for EGFR T790M mutations in patients Lung Cancer Molecular Testing Guideline Update—Lindeman et al 321